Leadiant Biosciences, Inc. today announced that Health Canada has approved Cysklar® (cysteamine ophthalmic solution) 0.44%, a topical eye drop solution indicated for the treatment of corneal cystine crystal accumulation in…
Read More
Leadiant Biosciences, Inc. today announced it has entered into a license agreement and cooperative research and development agreement (CRADA) with the National Institutes of Health (NIH) to develop oral N-acetyl-D-mannosamine…
Read More
Gaithersburg, MD, (February 28, 2017) – Sigma-Tau Pharmaceuticals, Inc., a leader in the development and commercialization of medicines for patients with rare diseases, today announced that the company has changed…
Read More
